Information Provided By:
Fly News Breaks for March 30, 2016
OPK
Mar 30, 2016 | 09:25 EDT
Ladenburg analyst Kevin DeGeeter encourages investors to use any weakness in OPKO Health's stock price as an "attractive opportunity" to accumulate shares. The company received a Complete Response Letter from FDA due to third party manufacturing issues for oral Rayaldee at 30mcg daily in the treatment of secondary hyperparathyroidism, but the analyst does not expect it to have a "material impact" on his projected Q3 Rayaldee launch. DeGeeter reiterates his Buy rating and $20 price target on the shares.
News For OPK From the Last 2 Days
OPK
Mar 28, 2024 | 16:23 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
OPK
Mar 28, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
OPK
Mar 28, 2024 | 08:03 EDT
Labcorp (LH) and OPKO Health (OPK) announce that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health across the United States outside of New York and New Jersey. This transaction includes patient service centers and certain customer contracts and operating assets. BioReference Health will continue to offer oncology and urology diagnostic services nationwide, as well as maintain its full operations in New York and New Jersey. When complete, the transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions across the country. The assets that Labcorp will be acquiring currently generate approximately $100M in annual revenue. The purchase price for the transaction is $237.5M. The proposed acquisition meets Labcorp's strategic and financial criteria. The transaction is subject to customary closing conditions and applicable regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The transaction is anticipated to close in the second half of 2024.